# A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

> **NCT03149991** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 51 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Ketamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03149991
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-14
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-06-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149991, "A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03149991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*